Tauopathies Treatment Market, by Disease (Frontoyemporal Degenration [Pick’s Disease, CBD, and PSP], Alzheimer’s Disease, and Other Neurodegenerative Diseases), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and by Region

Tauopathies Treatment Market, by Disease (Frontoyemporal Degenration [Pick’s Disease, CBD, and PSP], Alzheimer’s Disease, and Other Neurodegenerative Diseases), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Tauopathies are clinically, morphologically, and biochemically heterogeneous neurodegenerative diseases that are characterized by the tau protein aggregation in the brain. Currently, there are no approved treatments for tauopathies. The most common disease associated with tauopathy is Alzheimer’s disease. Characteristic symptoms and signs of tauopathies include changes in social behavior, personality, difficulty in making decisions, speaking, poor coordination and balance, dementia, and psychiatric symptoms.
Market Dynamics
Tauopathy includes various neurodegenerative conditions such as corticobasal degeneration, and progressive supranuclear palsy caused by the aggregation of tau protein in the brain. The growing number of patients affected with such conditions is expected to drive the market growth. The National Organization for Rare Disorders stated that corticobasal degeneration affects over 5 people per 100,000 in the general population, with around 60 to 90 new cases per 100,000 people yearly. Additionally, ongoing research and development of novel drugs and the rising prevalence of dementia are expected to impel the tauopathies treatment market growth in the projected timeframe. According to the World Health Organization’s statistics, each year, nearly 50 million people are diagnosed with dementia all across the globe.
Moreover, key players of the market are involved in clinical trials to develop, create, and commercialize novel drugs which are expected to favor growth of the global tauopathies treatment market in the coming future. However, delay in diagnosis and non-availability of approved drugs are expected to restrict the market growth during the forecast period.
Key features of the study:
This report provides in-depth analysis of the global tauopathies treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global tauopathies treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study are Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., AB Science, Cortice Biosciences, REGENXBIO Inc., Aquinnah Pharmaceuticals, Neurimmune, Oligomerix, Inc., Biogen, TauRx, Sellas, Selvita S.A, Bristol-Myers Squibb Company, Chronos Therapeutics Limited, and SK Biopharmaceuticals Co., Ltd.
Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global recurrent tauopathies treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the tauopathies treatment market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Tauopathies Treatment Market, By Disease:
Frontotemporal Degeneration
Pick’s Disease
Corticobasal Degeneration (CBD)
Progressive Supranuclear Palsy (PSP)
Alzheimer’s Disease
Other Neurodegenerative Diseases
Global Tauopathies Treatment Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Sales
Global Tauopathies Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Disease:
Frontotemporal Degeneration
Pick’s Disease
Corticobasal Degeneration (CBD)
Progressive Supranuclear Palsy (PSP)
Alzheimer’s Disease
Other Neurodegenerative Diseases
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Sales
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Disease:
Frontotemporal Degeneration
Pick’s Disease
Corticobasal Degeneration (CBD)
Progressive Supranuclear Palsy (PSP)
Alzheimer’s Disease
Other Neurodegenerative Diseases
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Sales
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Disease:
Frontotemporal Degeneration
Pick’s Disease
Corticobasal Degeneration (CBD)
Progressive Supranuclear Palsy (PSP)
Alzheimer’s Disease
Other Neurodegenerative Diseases
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Sales
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Disease:
Frontotemporal Degeneration
Pick’s Disease
Corticobasal Degeneration (CBD)
Progressive Supranuclear Palsy (PSP)
Alzheimer’s Disease
Other Neurodegenerative Diseases
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Sales
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Disease:
Frontotemporal Degeneration
Pick’s Disease
Corticobasal Degeneration (CBD)
Progressive Supranuclear Palsy (PSP)
Alzheimer’s Disease
Other Neurodegenerative Diseases
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Sales
Others
Company Profiles
Avanir Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Otsuka Pharmaceutical Co. Ltd.
AB Science
Cortice Biosciences.
REGENXBIO Inc.
Aquinnah Pharmaceuticals
Neurimmune
Oligomerix, Inc.
Biogen
TauRx
Sellas
Selvita S.A
Bristol-Myers Squibb Company
Chronos Therapeutics Limited
SK Biopharmaceuticals Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section